Model | Cases | Anti-LPS IgG + IgA | Anti-flagellin IgG + IgA | Anti-LPS IgG + anti-flagellin IgG | Anti-LPS IgA + anti-flagellin IgA | Anti-LPS IgG + IgA + anti-flagellin IgG + IgA |
---|---|---|---|---|---|---|
Stratified analyses | ||||||
By sex | ||||||
Men | 98 | 5.12 (2.09–12.55) | 5.58 (2.11–14.78) | 4.93 (2.06–11.79) | 2.34 (1.38–3.97) | 2.65 (1.58–4.45) |
Women | 41 | 1.61 (0.58–4.44) | 1.54 (0.54–4.36) | 1.21 (0.43–3.41) | 1.71 (0.72–4.03) | 1.34 (0.75–2.41) |
P interaction by sex | 0.062 | 0.059 | 0.030 | 0.402 | 0.055 | |
Cases diagnosed | ||||||
>2 years since blood collection | 117 | 2.75 (1.62–4.67) | 2.04 (1.29–3.21) | 2.35 (1.38–4.01) | 2.05 (1.33–3.15) | 1.68 (1.27–2.23) |
>4 years since blood collection | 97 | 4.87 (2.18–10.89) | 2.52 (1.4–4.54) | 3.70 (1.64–8.34) | 2.52 (1.47–4.33) | 2.11 (1.41–3.15) |
By follow-up timea | ||||||
< 6 y since blood collection | 65 | 2.45 (1.41–4.26) | 2.17 (1.27–3.73) | 2.43 (1.36–4.37) | 1.89 (1.20–2.95) | 1.67 (1.22–2.29) |
≥ 6 y since blood collection | 74 | 3.16 (1.65–6.06) | 2.57 (1.42–4.64) | 2.56 (1.38–4.77) | 2.23 (1.36–3.63) | 1.82 (1.30–2.56) |
Sensitivity analyses | ||||||
All data, subset with data on HBV/HCV status | 100 | 2.83 (1.61–4.99) | 2.62 (1.43–4.81) | 2.88 (1.61–5.15) | 1.95 (1.24–3.06) | 1.83 (1.32–2.55) |
Additionally adjusted for | ||||||
Liver damage scoreb | 100 | 2.92 (1.02–8.40) | 1.76 (0.83–3.72) | 2.86 (1.03–7.92) | 1.41 (0.75–2.64) | 1.56 (0.96–2.51) |
HBV/HCV status and liver damage scoreb | 100 | 3.35 (0.82–13.77) | 1.66 (0.62–4.44) | 2.35 (0.81–6.79) | 1.33 (0.64–2.77) | 1.60 (0.83–3.06) |